ClinicalTrials.gg
CompletedNCT03960645Updated Jun 14, 2024Results posted

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

A Phase 1 interventional study of B/F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Completed at 8 sites in 3 countries. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2024-06-14.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years to 39 Years
Sex
Female
01

Study summary

The primary objective of this study is to evaluate the steady state PK of bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose combination (FDC) in HIV-1 infected, virologically suppressed pregnant women in their second and third trimesters.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • With singleton pregnancy, at least 12 weeks but not more than 31 weeks pregnant at the time of screening
  • Agree not to breastfeed for the duration of the study
  • Currently on a stable antiretroviral regimen for ≥ 6 months preceding the screening visit
  • Documented plasma -1 ribonucleic acid (RNA) levels of \< 50 copies/mL for ≥ 6 months preceding the screening visit and have HIV-1 RNA \< 50 copies/mL at the screening visit
  • Have no documented or suspected resistance to FTC, Tenofovir (TFV), or integrase strand-transfer inhibitors (INSTIs) including, but not limited to, the reverse transcriptase resistance mutations K65R or M184V/I
  • Have a normal ultrasound, completed locally prior to the Day 1 visit, with no evidence of any fetal malformation or structural abnormality affecting either fetus or placenta
  • Normal maternal alfa-fetoprotein level at the screening visit

Key Exclusion Criteria:

  • Have chronic virus (HBV)
  • Have active virus (HCV) infection
  • An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    B/F/TAF

    Pregnant women participants will receive fixed dose combination (FDC) tablet of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for up to 38 weeks (from the second or third trimesters of pregnancy, depending on enrollment, through 12 weeks post-partum).

    Drug: B/F/TAF

  • No intervention
    Neonates

    Neonates who will be born to women participants in the study will be followed from birth up to 8 weeks of age after obtaining consent from the parent or legal guardian. None of the neonates that participate in the study will be treated with the study drug.

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUCtau of Bictegravir (BIC)

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

Secondary outcomes

  1. PK Parameter: AUCtau of Emtricitabine (FTC) and Tenofovir Alafenamide (TAF)

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  2. PK Parameter: AUClast of BIC, FTC, and TAF

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  3. PK Parameter: Cmax of BIC, FTC, and TAF

    Cmax is defined as the maximum observed concentration of drug during the dosing interval.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  4. PK Parameter: Ctau of BIC and FTC

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  5. PK Parameter: Clast of BIC, FTC, and TAF

    Clast is defined as the last observable concentration of drug.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  6. PK Parameter: Tmax of BIC, FTC, and TAF

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  7. PK Parameter: t1/2 of BIC, FTC, and TAF

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  8. PK Parameter: CLss/F of BIC, FTC, and TAF

    CLss/F is defined as the apparent steady-state oral clearance following administration of the drug.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  9. PK Parameter: Vz/F of BIC, FTC, and TAF

    Vz/F is defined as the apparent volume of distribution of the drug.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  10. PK Parameter: λz of BIC, FTC, and TAF

    λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.

    Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum

  11. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at the Time of Delivery Using the Missing = Excluded Approach in B/F/TAF Group

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at the time of delivery was analyzed in B/F/TAF group using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

    Time frame: At time of delivery

  12. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Birth Using the Missing = Excluded Approach in Neonates

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at the time of birth was analyzed in neonates using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

    Time frame: At birth

07

Results

Posted May 28, 2024

Participant flow

Participants were enrolled at study sites in the Dominican Republic, Thailand and the United States.

Participant flow — Overall Study
MilestoneB/F/TAFNeonates
Started3329
Completed3229
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: AUCtau of Bictegravir (BIC)

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · hours*nanograms per milliliter (h*ng/mL)
Pharmacokinetic (PK) Parameter: AUCtau of Bictegravir (BIC)
hours*nanograms per milliliter (h*ng/mL)B/F/TAF
Second Trimester62772.2 ± 20242.18
Third Trimester60163.4 ± 17482.06
Week 6 Post-partum134820.3 ± 36217.30
Week 12 Post-partum148251.6 ± 42189.17
Statistical analysis
  • B/F/TAF · Glsm ratio (%): 41.24 · 90% CI 36.71 to 46.32
  • B/F/TAF · Glsm ratio (%): 44.65 · 90% CI 40.04 to 49.79
  • B/F/TAF · Glsm ratio (%): 40.57 · 90% CI 36.77 to 44.76
  • B/F/TAF · Glsm ratio (%): 44.40 · 90% CI 39.95 to 49.34
SecondaryPK Parameter: AUCtau of Emtricitabine (FTC) and Tenofovir Alafenamide (TAF)

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · h*ng/mL
PK Parameter: AUCtau of Emtricitabine (FTC) and Tenofovir Alafenamide (TAF)
h*ng/mLB/F/TAF
FTC: Second Trimester10263.8 ± 2054.35
FTC: Third Trimester10435.2 ± 2121.87
FTC: Week 6 Post-partum16277.5 ± 4023.42
FTC: Week 12 Post-partum15308.5 ± 3359.83
TAF: Second Trimester235.5 ± 107.36
TAF: Third Trimester212.1 ± 95.38
TAF: Week 6 Post-partum374.3 ± 153.54
TAF: Week 12 Post-partum296.4 ± 94.37
Statistical analysis
  • B/F/TAF · Glsm ratio (%): 67.38 · 90% CI 63.45 to 71.56
  • B/F/TAF · Glsm ratio (%): 64.26 · 90% CI 60.95 to 67.75
  • B/F/TAF · Glsm ratio (%): 69.19 · 90% CI 65.88 to 72.66
  • B/F/TAF · Glsm ratio (%): 65.09 · 90% CI 61.79 to 68.57
  • B/F/TAF · Glsm ratio (%): 77.62 · 90% CI 65.40 to 92.14
  • B/F/TAF · Glsm ratio (%): 62.50 · 90% CI 50.76 to 76.96
  • B/F/TAF · Glsm ratio (%): 69.67 · 90% CI 58.57 to 82.88
  • B/F/TAF · Glsm ratio (%): 56.52 · 90% CI 46.32 to 68.96
SecondaryPK Parameter: AUClast of BIC, FTC, and TAF

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · h*ng/mL
PK Parameter: AUClast of BIC, FTC, and TAF
h*ng/mLB/F/TAF
BIC: Second Trimester63187.5 ± 19814.99
BIC: Third Trimester60145.3 ± 17484.52
BIC: Week 6 Post-partum135058.9 ± 36348.21
BIC: Week 12 Post-partum148265.3 ± 42201.47
FTC: Second Trimester10258.5 ± 2049.53
FTC: Third Trimester10434.2 ± 2121.13
FTC: Week 6 Post-partum16329.7 ± 4095.44
FTC: Week 12 Post-partum15308.5 ± 3359.79
TAF: Second Trimester220.4 ± 98.98
TAF: Third Trimester202.2 ± 84.98
TAF: Week 6 Post-partum356.7 ± 151.27
TAF: Week 12 Post-partum294.3 ± 97.88
SecondaryPK Parameter: Cmax of BIC, FTC, and TAF

Cmax is defined as the maximum observed concentration of drug during the dosing interval.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · ng/mL
PK Parameter: Cmax of BIC, FTC, and TAF
ng/mLB/F/TAF
BIC: Second Trimester5819.0 ± 1752.29
BIC: Third Trimester5374.7 ± 1393.86
BIC: Week 6 Post-partum9765.5 ± 2274.93
BIC: Week 12 Post-partum11025.3 ± 2747.42
FTC: Second Trimester2639.1 ± 965.60
FTC: Third Trimester2586.0 ± 686.42
FTC: Week 6 Post-partum3394.8 ± 951.83
FTC: Week 12 Post-partum3360.0 ± 902.47
TAF: Second Trimester332.4 ± 173.29
TAF: Third Trimester270.9 ± 113.93
TAF: Week 6 Post-partum506.4 ± 249.33
TAF: Week 12 Post-partum494.6 ± 259.51
Statistical analysis
  • B/F/TAF · Glsm ratio (%): 51.91 · 90% CI 46.48 to 57.97
  • B/F/TAF · Glsm ratio (%): 57.67 · 90% CI 52.48 to 63.36
  • B/F/TAF · Glsm ratio (%): 48.18 · 90% CI 43.03 to 53.94
  • B/F/TAF · Glsm ratio (%): 54.42 · 90% CI 48.39 to 61.21
  • B/F/TAF · Glsm ratio (%): 75.61 · 90% CI 66.70 to 85.70
  • B/F/TAF · Glsm ratio (%): 77.81 · 90% CI 68.76 to 88.05
  • B/F/TAF · Glsm ratio (%): 77.45 · 90% CI 70.33 to 85.29
  • B/F/TAF · Glsm ratio (%): 77.08 · 90% CI 69.78 to 85.15
  • B/F/TAF · Glsm ratio (%): 69.90 · 90% CI 56.16 to 87.00
  • B/F/TAF · Glsm ratio (%): 66.55 · 90% CI 53.79 to 82.34
  • B/F/TAF · Glsm ratio (%): 57.14 · 90% CI 46.04 to 70.91
  • B/F/TAF · Glsm ratio (%): 55.27 · 90% CI 44.65 to 68.42
SecondaryPK Parameter: Ctau of BIC and FTC

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · ng/mL
PK Parameter: Ctau of BIC and FTC
ng/mLB/F/TAF
BIC: Second Trimester1046.4 ± 472.68
BIC: Third Trimester1072.4 ± 447.03
BIC: Week 6 Post-partum3530.3 ± 1354.20
BIC: Week 12 Post-partum3641.9 ± 1241.64
FTC: Second Trimester59.8 ± 62.17
FTC: Third Trimester51.4 ± 13.98
FTC: Week 6 Post-partum152.1 ± 271.50
FTC: Week 12 Post-partum81.1 ± 27.34
Statistical analysis
  • B/F/TAF · Glsm ratio (%): 26.17 · 90% CI 21.45 to 31.93
  • B/F/TAF · Glsm ratio (%): 26.99 · 90% CI 22.23 to 32.78
  • B/F/TAF · Glsm ratio (%): 29.03 · 90% CI 25.74 to 32.74
  • B/F/TAF · Glsm ratio (%): 29.97 · 90% CI 26.47 to 33.93
  • B/F/TAF · Glsm ratio (%): 64.22 · 90% CI 54.63 to 75.49
  • B/F/TAF · Glsm ratio (%): 42.89 · 90% CI 36.55 to 50.34
  • B/F/TAF · Glsm ratio (%): 64.71 · 90% CI 59.30 to 70.61
  • B/F/TAF · Glsm ratio (%): 46.92 · 90% CI 39.57 to 55.64
SecondaryPK Parameter: Clast of BIC, FTC, and TAF

Clast is defined as the last observable concentration of drug.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · ng/mL
PK Parameter: Clast of BIC, FTC, and TAF
ng/mLB/F/TAF
BIC: Second Trimester1141.10 ± 631.431
BIC: Third Trimester1075.13 ± 447.847
BIC: Week 6 Post-partum3535.48 ± 1371.162
BIC: Week 12 Post-partum3641.88 ± 1240.605
FTC: Second Trimester75.08 ± 130.792
FTC: Third Trimester51.65 ± 14.182
FTC: Week 6 Post-partum156.16 ± 292.579
FTC: Week 12 Post-partum81.18 ± 27.334
TAF: Second Trimester4.49 ± 5.130
TAF: Third Trimester4.80 ± 4.048
TAF: Week 6 Post-partum3.13 ± 1.849
TAF: Week 12 Post-partum3.36 ± 1.999
SecondaryPK Parameter: Tmax of BIC, FTC, and TAF

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Median · h
PK Parameter: Tmax of BIC, FTC, and TAF
hB/F/TAF
BIC: Second Trimester2.00 (1.00 to 12.00)
BIC: Third Trimester2.00 (1.00 to 6.00)
BIC: Week 6 Post-partum1.50 (0.50 to 12.00)
BIC: Week 12 Post-partum1.50 (0.50 to 4.00)
FTC: Second Trimester1.50 (0.50 to 4.00)
FTC: Third Trimester1.50 (0.50 to 4.00)
FTC: Week 6 Post-partum1.50 (0.50 to 4.00)
FTC: Week 12 Post-partum1.00 (0.50 to 3.00)
TAF: Second Trimester0.75 (0.25 to 4.00)
TAF: Third Trimester1.00 (0.25 to 3.00)
TAF: Week 6 Post-partum0.75 (0.25 to 3.00)
TAF: Week 12 Post-partum0.75 (0.25 to 3.00)
SecondaryPK Parameter: t1/2 of BIC, FTC, and TAF

t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Median · h
PK Parameter: t1/2 of BIC, FTC, and TAF
hB/F/TAF
BIC: Second Trimester9.09 (4.75 to 16.04)
BIC: Third Trimester9.91 (7.53 to 16.24)
BIC: Week 6 Post-partum18.24 (12.18 to 29.59)
BIC: Week 12 Post-partum17.27 (4.534 to 26.3)
FTC: Second Trimester6.43 (4.76 to 7.36)
FTC: Third Trimester6.41 (4.49 to 7.91)
FTC: Week 6 Post-partum6.27 (4.47 to 7.80)
FTC: Week 12 Post-partum5.76 (3.83 to 8.19)
TAF: Second Trimester0.30 (0.22 to 0.66)
TAF: Third Trimester0.28 (0.19 to 0.62)
TAF: Week 6 Post-partum0.40 (0.25 to 0.60)
TAF: Week 12 Post-partum0.35 (0.25 to 0.60)
SecondaryPK Parameter: CLss/F of BIC, FTC, and TAF

CLss/F is defined as the apparent steady-state oral clearance following administration of the drug.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · mL/h
PK Parameter: CLss/F of BIC, FTC, and TAF
mL/hB/F/TAF
BIC: Second Trimester911.78 ± 433.301
BIC: Third Trimester902.47 ± 287.285
BIC: Week 6 Post-partum399.02 ± 113.214
BIC: Week 12 Post-partum362.40 ± 95.856
FTC: Second Trimester20228.02 ± 3981.186
FTC: Third Trimester19975.85 ± 4223.365
FTC: Week 6 Post-partum12991.62 ± 3111.349
FTC: Week 12 Post-partum13645.71 ± 2830.897
TAF: Second Trimester122677.74 ± 44270.041
TAF: Third Trimester135061.19 ± 44876.970
TAF: Week 6 Post-partum76939.32 ± 29189.555
TAF: Week 12 Post-partum92888.59 ± 29461.550
SecondaryPK Parameter: Vz/F of BIC, FTC, and TAF

Vz/F is defined as the apparent volume of distribution of the drug.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · mL
PK Parameter: Vz/F of BIC, FTC, and TAF
mLB/F/TAF
BIC: Second Trimester11896.24 ± 4417.149
BIC: Third Trimester13406.77 ± 4349.429
BIC: Week 6 Post-partum10348.47 ± 3713.380
BIC: Week 12 Post-partum8692.59 ± 2398.645
FTC: Second Trimester181767.32 ± 36739.344
FTC: Third Trimester184791.79 ± 56340.526
FTC: Week 6 Post-partum117384.90 ± 35385.941
FTC: Week 12 Post-partum117660.87 ± 33240.095
TAF: Second Trimester62333.17 ± 37242.307
TAF: Third Trimester53230.98 ± 16727.325
TAF: Week 6 Post-partum44440.06 ± 13678.515
TAF: Week 12 Post-partum49837.70 ± 22019.454
SecondaryPK Parameter: λz of BIC, FTC, and TAF

λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.

Time frame:
Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Reported as:
Mean · 1/h
PK Parameter: λz of BIC, FTC, and TAF
1/hB/F/TAF
BIC: Second Trimester0.077 ± 0.0231
BIC: Third Trimester0.068 ± 0.0125
BIC: Week 6 Post-partum0.040 ± 0.0098
BIC: Week 12 Post-partum0.043 ± 0.0134
FTC: Second Trimester0.113 ± 0.0142
FTC: Third Trimester0.112 ± 0.0173
FTC: Week 6 Post-partum0.114 ± 0.0151
FTC: Week 12 Post-partum0.120 ± 0.0209
TAF: Second Trimester2.227 ± 0.7128
TAF: Third Trimester2.550 ± 0.7519
TAF: Week 6 Post-partum1.777 ± 0.4685
TAF: Week 12 Post-partum1.954 ± 0.4519
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at the Time of Delivery Using the Missing = Excluded Approach in B/F/TAF Group

The percentage of participants with HIV-1 RNA \< 50 copies/mL at the time of delivery was analyzed in B/F/TAF group using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

Time frame:
At time of delivery
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at the Time of Delivery Using the Missing = Excluded Approach in B/F/TAF Group
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at the Time of Delivery Using the Missing = Excluded Approach in B/F/TAF Group100.0 (89.1 to 100.0)
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Birth Using the Missing = Excluded Approach in Neonates

The percentage of participants with HIV-1 RNA \< 50 copies/mL at the time of birth was analyzed in neonates using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

Time frame:
At birth
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Birth Using the Missing = Excluded Approach in Neonates
percentage of participantsNeonates
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Birth Using the Missing = Excluded Approach in Neonates100.0 (15.8 to 100.0)

Adverse events

Collected over All-Cause Mortality: From birth up to 8 weeks of age for neonates; From enrollment up to 38 weeks + 30 days for B/F/TAF group. Adverse Events: First dose date up to 38 weeks + 30 days for B/F/TAF group. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B/F/TAF0/33 (0%)6/33 (18.2%)19/33 (57.6%)
Neonates0/29 (0%)5/29 (17.2%)4/29 (13.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventB/F/TAFNeonates
False labourPregnancy, puerperium and perinatal conditions3/330/29
Accessory auricleCongenital, familial and genetic disorders0/331/29
Atrial septal defectCongenital, familial and genetic disorders0/331/29
Sepsis neonatalInfections and infestations0/331/29
Jaundice neonatalPregnancy, puerperium and perinatal conditions0/331/29
Neonatal asphyxiaRespiratory, thoracic and mediastinal disorders0/331/29
Transient tachypnoea of the newbornRespiratory, thoracic and mediastinal disorders0/331/29
Nonreassuring foetal heart rate patternCardiac disorders1/330/29
PyrexiaGeneral disorders1/330/29
Covid-19Infections and infestations1/330/29
Most frequent other events
Showing 10 of 13
Most frequent other events
EventB/F/TAFNeonates
Back painMusculoskeletal and connective tissue disorders4/330/29
Gestational diabetesPregnancy, puerperium and perinatal conditions4/330/29
Respiratory distressRespiratory, thoracic and mediastinal disorders0/333/29
AnaemiaBlood and lymphatic system disorders3/330/29
Jaundice neonatalPregnancy, puerperium and perinatal conditions0/332/29
Foetal heart rate deceleration abnormalityCardiac disorders2/330/29
Abdominal painGastrointestinal disorders2/330/29
HaemorrhoidsGastrointestinal disorders2/330/29
DizzinessNervous system disorders2/330/29
HeadacheNervous system disorders2/330/29

Baseline characteristics

B/F/TAF: Safety analysis set included all adult participants who took at least 1 dose of study drug (B/F/TAF). Neonates: Safety analysis set included neonates who were born to women participating in the study and had been enrolled into the study as well.

Age, Continuous
Age, Continuous(years)B/F/TAFNeonatesTotal
Mean30 ± 5.00 ± 0.016 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAFNeonatesTotal
Female331043
Male01919
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)B/F/TAFNeonatesTotal
Hispanic or Latino448
Not Hispanic or Latino292554
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFNeonatesTotal
Race — Asian252449
Race — Black6410
Race — Other112
Race — White101
Region of Enrollment
Region of Enrollment(Participants)B/F/TAFNeonatesTotal
Thailand252449
United States527
Dominican Republic336
08

Study locations

8 sites
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33407, United States
  • Instituto Dominicano de Estudios Virologics (IDEV)
    Santo Domingo, 10103, Dominican Republic
  • Faculty of Medicine Siriraj Hospital
    Bangkok Noi, 10700, Thailand
  • Faculty of Medicine-Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Bamrasnaradura Infectious Diseases Institute
    Mueang Nonthaburi, 11000, Thailand
  • Research Institute for Health Sciences, Chiang Mai University
    Mueang Nonthaburi, 50200, Thailand
  • Thai Red Cross AIDS Research Centre
    Pathumwan, 10330, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Jul 2022, 36 months.

Results were first posted in May 2024, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 23, 2019
StartActual
Jun 28, 2019
Primary completionActual
Jul 21, 2022
CompletionActual
Aug 18, 2022
Results first posted
May 28, 2024
Last update
Jun 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03960645
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Jun 28, 2019
Primary completion
Jul 21, 2022
Completion
Aug 18, 2022
Results posted
May 28, 2024
Last update
Jun 14, 2024

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion